Linsitinib (OSI-906)

目录号:S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献33篇:

客户使用该产品的6个实验数据:

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂,在无细胞试验中IC50为35 nM;对InsR抑制作用适中,IC50为75 nM,对Abl,ALK,BTK,EGFR, FGFR1/2,PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活,IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体,具有良好的代谢稳定性。OSI-906浓度为1μM时,完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖,包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系,EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHCcHFMUUN3ME2wMlAzQDB4IN88US=> MnfGV2FPT0WU
KS-1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTCVWREUUN3ME2wMlA{QDN3IN88US=> M4n4ZXNCVkeHUh?=
TE-11 NYn6eG5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEe4NlIh|ryP M4C5V3NCVkeHUh?=
EW-1 NGrLenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEi1PFUh|ryP M2XMTnNCVkeHUh?=
HMV-II MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP5ZZBKSzVyPUCuNFg5PDZizszN M{DRTHNCVkeHUh?=
COLO-205 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjvOI1wUUN3ME2wMlExPDV2IN88US=> M{jMU3NCVkeHUh?=
ES1 MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\sWmJKSzVyPUCuNVA3QTZizszN M4PpeHNCVkeHUh?=
GDM-1 NFHrem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDmNYhQUUN3ME2wMlE{Pjd{IN88US=> NF7OSXJUSU6JRWK=
ML-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkntTWM2OD1yLkG1PFk3KM7:TR?= MX;TRW5ITVJ?
Saos-2 NFTPWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrZW|hEUUN3ME2wMlE3PTJ4IN88US=> NV\x[4JqW0GQR1XS
NCI-H1355 M2P1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTQTWM2OD1yLkG4NVM2KM7:TR?= NHTa[WRUSU6JRWK=
G-401 M331VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzpO|VKSzVyPUCuNVgzOyEQvF2= NXzjWmxFW0GQR1XS
EW-16 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUi3O|ch|ryP NFXp[GtUSU6JRWK=
EW-7 NWPGZ|JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jDbGlEPTB;MD6xPFg5OSEQvF2= MY\TRW5ITVJ?
NCI-H727 NHPJTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL0TWM2OD1yLkG5O|k1KM7:TR?= NFnlSpNUSU6JRWK=
LCLC-97TM1 NVfZbnZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:xeWlEPTB;MD6yNFk2PSEQvF2= MnTXV2FPT0WU
NCI-H650 NUHYO3QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTocodjUUN3ME2wMlIyOzh2IN88US=> NHHldmpUSU6JRWK=
NCI-H2122 NHnVZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTid3lKSzVyPUCuNlMzQTlizszN NGn1W4tUSU6JRWK=
SK-N-DZ MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\xTWM2OD1yLkKzOlk5KM7:TR?= MV3TRW5ITVJ?
HT-29 NGX1OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkWZdvUUN3ME2wMlI1OjR6IN88US=> Mn7EV2FPT0WU
LB771-HNC NWjSUmtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMkW5NVUh|ryP MliwV2FPT0WU
HT-144 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYniV3dSUUN3ME2wMlI3OTlzIN88US=> MYrTRW5ITVJ?
LAN-6 NF3wS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMk[zOFgh|ryP NEDJeXZUSU6JRWK=
EW-18 M4DCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD1yLkK3NFAyKM7:TR?= NYnEOFFQW0GQR1XS
LS-1034 NU[2bpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvTTWM2OD1yLkK3NVMzKM7:TR?= MoPOV2FPT0WU
EW-11 NHj0UWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\B[WtHUUN3ME2wMlI5PDN{IN88US=> MVTTRW5ITVJ?
SNU-C1 M2n2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC3W5VSUUN3ME2wMlI6OzF|IN88US=> MUjTRW5ITVJ?
RS4-11 NEDpe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwM{O3OVgh|ryP NWTVd2tPW0GQR1XS
ES4 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn20TWM2OD1yLkSxNFM5KM7:TR?= NEOx[nFUSU6JRWK=
COLO-320-HSR NWrqXZlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDW[JREUUN3ME2wMlQyOzZ6IN88US=> NWXkVI5mW0GQR1XS
NB10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfYTWM2OD1yLkS1OFM4KM7:TR?= NVzPbZlbW0GQR1XS
BFTC-905 NUjhNXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom5TWM2OD1yLkS2O|U5KM7:TR?= MYHTRW5ITVJ?
A375 M1zpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNEe2NVch|ryP NUDMWVlMW0GQR1XS
SJRH30 NXPnT49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTj[GJmUUN3ME2wMlUxQDJ{IN88US=> NXnKeplIW0GQR1XS
NOS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYVJNXUUN3ME2wMlUzOjZ5IN88US=> MXHTRW5ITVJ?
SIG-M5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjSZ45KSzVyPUCuOVM2PTdizszN Mk\vV2FPT0WU
DOK NFHKVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi5TWM2OD1yLkW1OkDPxE1? MYjTRW5ITVJ?
NB69 M33kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTUTWM2OD1yLkW4NlU4KM7:TR?= NYPxW2t4W0GQR1XS
SK-NEP-1 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HDbWlEPTB;MD62NFI{PiEQvF2= MkPlV2FPT0WU
SK-MM-2 NEf0bnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwNkW0PVEh|ryP NEHQTodUSU6JRWK=
NCI-H358 NHryNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\4N41WUUN3ME2wMlY4ODh{IN88US=> MoXwV2FPT0WU
RH-1 NIWxcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tvb2lEPTB;MD63OFg2QSEQvF2= MXfTRW5ITVJ?
NH-12 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXtUGdKSzVyPUCuO|YxPDZizszN M2TzWXNCVkeHUh?=
TE-12 NVzORZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TzemlEPTB;MD63OlQ5PiEQvF2= MoTPV2FPT0WU
COLO-668 NHjoZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDqTWM2OD1yLki0OlY3KM7:TR?= MVjTRW5ITVJ?
PANC-08-13 M3rYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwOE[zO|ch|ryP NXLwNGhiW0GQR1XS
HCC2998 M1mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LET2lEPTB;MD64PFI3OyEQvF2= NYPmRVdyW0GQR1XS
ABC-1 M3LvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq5TWM2OD1yLkmwN|UzKM7:TR?= NXLLNIJ7W0GQR1XS
ES6 NVmzblQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwOUGwOlYh|ryP NXz3WJRyW0GQR1XS
SNU-387 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DxR2lEPTB;MD65PVM6OyEQvF2= NV;ZdZhKW0GQR1XS
CMK M3LPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwOUm5Nlkh|ryP MWHTRW5ITVJ?
SJSA-1 M3fsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\5TWM2OD1zLkCzOlU{KM7:TR?= NIrkZ2hUSU6JRWK=
SIMA MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwME[4NlUh|ryP NVLkbYFxW0GQR1XS
ES3 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\JSlFKSzVyPUGuNVIzQTdizszN NEm1OYhUSU6JRWK=
IGROV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSTWM2OD1zLkG1OFQ1KM7:TR?= NU\IbWxGW0GQR1XS
MEL-JUSO MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HJW2lEPTB;MT6xOVc2QSEQvF2= M363NnNCVkeHUh?=
T84 NUO2S|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXvTWM2OD1zLkKwPVE1KM7:TR?= NY[wPVNYW0GQR1XS
CAL-85-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37pe2lEPTB;MT6yN|E{QCEQvF2= M2HoenNCVkeHUh?=
RD NHzjcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n6d2lEPTB;MT6yOlQ2PSEQvF2= M3z0fXNCVkeHUh?=
TE-8 NX;1NpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4R4lUUUN3ME2xMlMyPDZ{IN88US=> MWjTRW5ITVJ?
L-363 NHnkU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrpUlVsUUN3ME2xMlM1OjB6IN88US=> MUTTRW5ITVJ?
EKVX NYPOXWZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDaTWM2OD1zLkO0OVY5KM7:TR?= MUXTRW5ITVJ?
SK-MEL-3 NIfXdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL6N2ZKSzVyPUGuOFg2PTZizszN MULTRW5ITVJ?
TGBC24TKB NXzHTpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fSeWlEPTB;MT61NFE6OyEQvF2= NXqxTHdDW0GQR1XS
NCI-H1770 M3vPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q0SWlEPTB;MT61NVEyOyEQvF2= M{KxOXNCVkeHUh?=
HuH-7 NYfiRnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XHeGlEPTB;MT62NFA6QCEQvF2= MUTTRW5ITVJ?
HL-60 M4W1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFwNk[5Nlgh|ryP NV;YUVlGW0GQR1XS
TE-1 NYfScVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK0WJRKSzVyPUGuO|A6PDVizszN NWLkfoVVW0GQR1XS
LC-2-ad MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwN{O4PFch|ryP NVLxWm5vW0GQR1XS
LB647-SCLC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[0fpdKSzVyPUGuO|Y2QDNizszN NHy1N4ZUSU6JRWK=
NCI-H2171 NEnOPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HmcmlEPTB;MT63O|cyPiEQvF2= MlzEV2FPT0WU
SK-PN-DW MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwOUGyPVgh|ryP NXTTO4QxW0GQR1XS
MC-IXC MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLGTWM2OD1zLkm4PVgh|ryP MXPTRW5ITVJ?
LS-513 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OyZWlEPTB;Mj6wOVMxPSEQvF2= M361c3NCVkeHUh?=
EW-3 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPQdHJrUUN3ME2yMlA6QDR2IN88US=> NVOyOXNmW0GQR1XS
OPM-2 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPhTWM2OD1{LkGwNkDPxE1? M13VdHNCVkeHUh?=
LP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwMkW4NFch|ryP MX7TRW5ITVJ?
LU-134-A NX:yVldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvZZpVKSzVyPUKuNlc4KM7:TR?= NXT6fVJxW0GQR1XS
CP66-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fJNmlEPTB;Mj6yPVAyPCEQvF2= MX;TRW5ITVJ?
HCC1143 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Yd3ByUUN3ME2yMlQ2OzZ6IN88US=> MXXTRW5ITVJ?
LOXIMVI NFjwV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13Gb2lEPTB;Mj62NFIyKM7:TR?= MUDTRW5ITVJ?
TE-10 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLrbHFnUUN3ME2yMlcxQDN6IN88US=> M3;QcHNCVkeHUh?=
NCI-H1882 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwN{WyNlch|ryP MYTTRW5ITVJ?
CHP-126 NGPJUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5[5lKUUN3ME2yMlc3OzF5IN88US=> MlLiV2FPT0WU
NCI-H1623 NYLpcnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDVWlEPTB;Mj65NlAzPCEQvF2= NGW2PFJUSU6JRWK=
GB-1 M{PLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm3TJZmUUN3ME2yMlk{PDB2IN88US=> MYHTRW5ITVJ?
RCC10RGB MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJwOUWyPFEh|ryP MUPTRW5ITVJ?
NCI-H2141 NWjGUHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvJTWM2OD1{Lkm2PFk3KM7:TR?= NGjhXm1USU6JRWK=
GI-ME-N NXPyT4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;xOVByUUN3ME2zMlAxPTZ3IN88US=> MoDXV2FPT0WU
NCI-H526 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe3VFVKSzVyPUOuNFQxQDVizszN M4fmRnNCVkeHUh?=
NCI-H747 NH7Dco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzGNXdTUUN3ME2zMlA1QTl{IN88US=> NHXqR4dUSU6JRWK=
SNU-423 M4rzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfRSlBLUUN3ME2zMlIxOzF|IN88US=> M{Tt[3NCVkeHUh?=
A427 NYfObFZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfSRZQ2UUN3ME2zMlI2Pjl7IN88US=> NFvTPZlUSU6JRWK=
CAL-12T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[xZXRkUUN3ME2zMlQxPzF|IN88US=> NV;3e5dXW0GQR1XS
LU-99A Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DaU2lEPTB;Mz60O|ExPSEQvF2= NVrYfYNmW0GQR1XS
MS-1 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\rTWM2OD1|LkWzOFI6KM7:TR?= MmrFV2FPT0WU
SK-LU-1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzUZdKSzVyPUOuO|YzQTVizszN MlTKV2FPT0WU
SW837 NVLnfZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L5UGlEPTB;Mz63OlM{OyEQvF2= MonrV2FPT0WU
ES8 NEKyfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNwOEO4O|ch|ryP NYizWIcyW0GQR1XS
MZ2-MEL MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwOUKwPFYh|ryP MYTTRW5ITVJ?
TGW M3iwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwMEGzNVEh|ryP M4fPNnNCVkeHUh?=
GP5d NYi3eHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHWfYdKSzVyPUSuNFU{PjJizszN M13VXnNCVkeHUh?=
BB49-HNC MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkexTWM2OD12LkG1NlE{KM7:TR?= NIjuWGxUSU6JRWK=
NB13 NHr0[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS2PINKSzVyPUSuNlY5QDdizszN MXjTRW5ITVJ?
NTERA-S-cl-D1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj5[2lKSzVyPUSuNlg3OTVizszN MYTTRW5ITVJ?
NCI-H1648 NX3WR4NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4SyT2lEPTB;ND6yPVgyQSEQvF2= NYfLfXp1W0GQR1XS
LCLC-103H M4GwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4fGdEUUN3ME20MlMzOTl3IN88US=> MnPyV2FPT0WU
LS-411N MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITXR29KSzVyPUSuOFQ5QDVizszN M2PJZ3NCVkeHUh?=
NCI-H1092 NGS4OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm3VWpKSzVyPUSuOFU3QDdizszN MYrTRW5ITVJ?
PANC-10-05 M3L5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XKUmlEPTB;ND62PVg1KM7:TR?= M4[wb3NCVkeHUh?=
DK-MG MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLwZng{UUN3ME20MlgxQTN|IN88US=> NVfiPVdpW0GQR1XS
OVCAR-5 NX;FdWNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD12LkixNlI3KM7:TR?= NVfjbVVwW0GQR1XS
CAL-39 NFjmSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\3XYZKSzVyPUSuPFc3PyEQvF2= NVy5VmtMW0GQR1XS
TE-441-T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETVPJhKSzVyPUSuPVA2OzdizszN MWTTRW5ITVJ?
MOLT-16 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGbmlEPTB;ND65OVI2OyEQvF2= M3HlNXNCVkeHUh?=
MCF7 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTVwMUS1NVch|ryP M3[1eXNCVkeHUh?=
CAPAN-1 NU[wbolMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK5OWlKSzVyPUWuNlU4ODdizszN M1:3VXNCVkeHUh?=
PSN1 Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmV2t1UUN3ME21MlI4OjN3IN88US=> NYXTNFhQW0GQR1XS
NCI-H292 NIrSbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;HWmlEPTB;NT6zNFA1PCEQvF2= MV\TRW5ITVJ?
CPC-N MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;PPZd1UUN3ME21MlM6PDF7IN88US=> MVnTRW5ITVJ?
DoTc2-4510 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTVwNEWzO|Eh|ryP Mk\IV2FPT0WU
LB1047-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7jenl5UUN3ME21MlU2QTN|IN88US=> NVTPUY1IW0GQR1XS
MHH-ES-1 NV3aUFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTVwNUm5NFch|ryP MmHZV2FPT0WU
NMC-G1 M4TPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTVwN{CyNlch|ryP MUnTRW5ITVJ?
SW1710 NGjFdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO0botKSzVyPUWuO|Q4PTFizszN NWTndWRGW0GQR1XS
YAPC NVnnOnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTVwN{[yNFEh|ryP MYDTRW5ITVJ?
22RV1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni2TWM2OD13LkiwNFE6KM7:TR?= M3nvZXNCVkeHUh?=
COLO-679 NIPoO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVwOEi5OFgh|ryP NYPFbplxW0GQR1XS
TCCSUP NY\3SGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDmTWM2OD13LkmzNlU6KM7:TR?= NWDt[HpQW0GQR1XS
C2BBe1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXFTWM2OD13LkmzPVch|ryP NWTjPZc4W0GQR1XS
TE-15 M1TY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwME[2NFUh|ryP NVnsO3hvW0GQR1XS
SCLC-21H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzTWM2OD14LkGwPFQ{KM7:TR?= MV;TRW5ITVJ?
EoL-1-cell MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHM[|FKSzVyPU[uNVY2PjNizszN NX7qVFRvW0GQR1XS
NKM-1 NGrPN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTZwMU[3NUDPxE1? M{XrfXNCVkeHUh?=
NCI-H1304 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD14LkK3OFI5KM7:TR?= MmrmV2FPT0WU
NB6 NHHPUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOzTplKSzVyPU[uNlk3OjJizszN MlnQV2FPT0WU
NALM-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZwM{OyN{DPxE1? NGixbWFUSU6JRWK=
NCI-H522 NVXQSINbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwM{OzNFYh|ryP MlTmV2FPT0WU
MV-4-11 NUHoXGx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzOoNKSzVyPU[uN|cxPzlizszN NX7ib|hOW0GQR1XS
LB2241-RCC NWDBOZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjZTWM2OD14LkO4OlY4KM7:TR?= MnHXV2FPT0WU
NCI-H1417 M1ryNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwNEC4OFch|ryP MU\TRW5ITVJ?
HT-1197 NVrieG5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nkO2lEPTB;Nj61O|EzOiEQvF2= M{H2NnNCVkeHUh?=
P30-OHK M2nVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorUTWM2OD14Lk[yO|ch|ryP NUTtdohuW0GQR1XS
ALL-PO MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHjcmlKSzVyPU[uO|E6OTZizszN MWXTRW5ITVJ?
OVCAR-4 NWXRVJJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xTWM2OD14Lke1OFA2KM7:TR?= MWDTRW5ITVJ?
HCC2157 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq5dZllUUN3ME22Mlc4PDd3IN88US=> NIP3TlFUSU6JRWK=
NCI-H838 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO2TWM2OD14Lkm2OFkh|ryP Mmf5V2FPT0WU
NCI-H1299 M3vOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjBXVRtUUN3ME22Mlk4ODlizszN NXPY[VJDW0GQR1XS
SW954 NH3SZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfUV4dKSzVyPUeuNlAxPjhizszN NW[2T2dSW0GQR1XS
NCI-H441 NWrQNWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeyT5lKSzVyPUeuN|QxPjVizszN MYnTRW5ITVJ?
SK-MEL-2 M4LZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvEN4twUUN3ME23MlQ5Ozd|IN88US=> M4fQUHNCVkeHUh?=
KARPAS-45 NUDGc4pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTdwNkW5Nlkh|ryP MX7TRW5ITVJ?
CAL-54 NXvSe2pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHFWlBKSzVyPUeuPFI6PzdizszN M{HhPHNCVkeHUh?=
KYSE-180 M3fO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTdwOEi5OFEh|ryP Mmi3V2FPT0WU
NCI-H187 NF;QdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTLclI2UUN3ME23Mlk2QTR5IN88US=> NHvIVm1USU6JRWK=
RT-112 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPYTWM2OD16LkC5Olc4KM7:TR?= NVLCR3dpW0GQR1XS
NCI-H1437 NIf0N|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThwMEm3PVUh|ryP NUHWbpI6W0GQR1XS
SNU-449 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PGNGlEPTB;OD6yPFI4OiEQvF2= NXO0W2QzW0GQR1XS
HCC1187 M4ixS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\NRYJKSzVyPUiuNlk{QTFizszN NX3ISohNW0GQR1XS
NCI-H2030 M{jwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojGTWM2OD16LkO3O|E1KM7:TR?= MlTnV2FPT0WU
HuO-3N1 M{TqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPpTWM2OD16LkO3PFQ1KM7:TR?= NVLuSJQ5W0GQR1XS
COLO-792 NWT2cpdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjQR|JKSzVyPUiuOFE2OjdizszN M3PQ[XNCVkeHUh?=
MIA-PaCa-2 NVfqTY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfhTVFKSzVyPUiuPFU2ODhizszN MX3TRW5ITVJ?
SK-N-FI MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDNTpdZUUN3ME25MlA1OjVizszN NUjrco9{W0GQR1XS
MMAC-SF NFzoXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLMTWM2OD17LkC5O|UyKM7:TR?= NWfsOGVqW0GQR1XS
NCI-H28 NVfqfHhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DaVGlEPTB;OT6xNFQ3QSEQvF2= NUP5SGdUW0GQR1XS
ETK-1 NIG1V2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrRRY1xUUN3ME25MlI6QTd2IN88US=> MVfTRW5ITVJ?
NCI-H1993 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPoTWM2OD17LkS0NlYyKM7:TR?= NV;Bdmd5W0GQR1XS
no-11 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL5R3lKSzVyPUmuOFcyOiEQvF2= M3XFc3NCVkeHUh?=
ChaGo-K-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrCc45UUUN3ME25MlUyPTh|IN88US=> NGDJOW5USU6JRWK=
NCCIT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rsNGlEPTB;OT61N|E3QSEQvF2= MXfTRW5ITVJ?
SAS NIrXfnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH1Z5hKSzVyPUGwMlI1QCEQvF2= NFH4eY9USU6JRWK=
A673 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLWTWM2OD1zMD6zO|A1KM7:TR?= M1ftV3NCVkeHUh?=
NCI-H1522 NFPnXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFyLkO3NFch|ryP NFzkUZZUSU6JRWK=
NCI-H810 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK1dZhQUUN3ME2xNE4{QTB5IN88US=> NEGxV|NUSU6JRWK=
IST-MES1 NEnXXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnWOlByUUN3ME2xNE41PTZ2IN88US=> NF3QS4VUSU6JRWK=
GR-ST MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nuOWlEPTB;MUCuOVAzPCEQvF2= MVHTRW5ITVJ?
SUP-T1 NX3jVpozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITDe|ZKSzVyPUGwMlc{OTdizszN NETKVFRUSU6JRWK=
NB5 NYHVfpNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HJTWlEPTB;MUCuPVAzOiEQvF2= NX7UXI03W0GQR1XS
MZ1-PC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjMTWM2OD1zMD65OVcyKM7:TR?= NInXXYZUSU6JRWK=
SK-CO-1 NYH2dItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;aPHFKSzVyPUGwMlk6OzFizszN M4HmNnNCVkeHUh?=
Capan-2 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnYTWM2OD1zMT6zNVk5KM7:TR?= M4TyfXNCVkeHUh?=
697 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\IdWV4UUN3ME2xNU43PzV5IN88US=> MkfsV2FPT0WU
REH MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvqTWM2OD1zMT63OFUyKM7:TR?= NH;ER2tUSU6JRWK=
GI-1 NYjVUFhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi5d3NLUUN3ME2xNU45PjF3IN88US=> M3:5ZnNCVkeHUh?=
BB65-RCC NF;0ZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhdphKSzVyPUGyMlA6OTZizszN Mof4V2FPT0WU
NCI-H1651 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTYTWM2OD1zMj6yOFc5KM7:TR?= MkTYV2FPT0WU
NCI-H1618 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQOmlEPTB;MUKuN|k4PiEQvF2= NGfKS41USU6JRWK=
NCI-H2081 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxcFZKSzVyPUGyMlYyPDFizszN MoLvV2FPT0WU
GCIY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXOUXlqUUN3ME2xNk44OjF|IN88US=> NXPzNWhLW0GQR1XS
NY MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\LWIxKSzVyPUGzMlA3PDNizszN M{OwdHNCVkeHUh?=
PANC-03-27 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF|LkC4NFch|ryP MlKwV2FPT0WU
BHY M2TjXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|LkKxNlEh|ryP NXHEcoI3W0GQR1XS
SK-OV-3 NIfJO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF|LkO3OlMh|ryP M{TBPHNCVkeHUh?=
5637 M4TBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf3Z|VKSzVyPUGzMlc4PTlizszN NXq2TlZJW0GQR1XS
LC-1F MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG1TWM2OD1zND6wN|U3KM7:TR?= NXjncWZPW0GQR1XS
SNB75 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF2LkCzPFMh|ryP Mnv6V2FPT0WU
CHP-212 NXOweJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF2LkC0OlQh|ryP MVLTRW5ITVJ?
HT-1376 NEPHWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wTWM2OD1zND6xNVI3KM7:TR?= Mmj5V2FPT0WU
MONO-MAC-6 NVHh[YlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInLeIdKSzVyPUG0MlE2ODJizszN MXjTRW5ITVJ?
CA46 NGKwOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJSGlEPTB;MUSuNVgzPyEQvF2= M{DKTHNCVkeHUh?=
SCC-15 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrSTWM2OD1zND61OVg{KM7:TR?= M4njPXNCVkeHUh?=
ATN-1 NVHlXY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfqRYNKSzVyPUG0MlY3OjdizszN M4rIO3NCVkeHUh?=
NCI-H2405 NWD3XJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwXXZKSzVyPUG0MlgyPTdizszN M1PuUHNCVkeHUh?=
NCI-H716 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{npTWlEPTB;MUSuPFQ6OyEQvF2= MXHTRW5ITVJ?
SW620 NXPxdmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;x[VFUUUN3ME2xOE46ODF2IN88US=> NHy2NlJUSU6JRWK=
NCI-H226 M1rkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF2LkmwPFUh|ryP M1rmTHNCVkeHUh?=
SW962 NVTodHdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrWTWM2OD1zND65OFMzKM7:TR?= MlHNV2FPT0WU
KYSE-150 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnETWM2OD1zND65OVUh|ryP NXzXXnNMW0GQR1XS
OCUB-M M{nwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfZTWM2OD1zND65PFg{KM7:TR?= MWLTRW5ITVJ?
ES7 M3zUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzZ[pZtUUN3ME2xOU4xQTh2IN88US=> NH7pOZRUSU6JRWK=
SW1463 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXhWJpKSzVyPUG1MlQzOjNizszN MUfTRW5ITVJ?
CAKI-1 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF3LkWzOFYh|ryP M{noUnNCVkeHUh?=
MKN28 M3L0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkW0O|kh|ryP NIrRbYVUSU6JRWK=
SW13 NEX3VpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfr[293UUN3ME2xOU43OThizszN M{n4U3NCVkeHUh?=
A3-KAW Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF3Lkm2PVch|ryP MUTTRW5ITVJ?
LU-65 NXHhV4h6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zMeWlEPTB;MUWuPVc3QCEQvF2= MorLV2FPT0WU
Calu-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Ce4FrUUN3ME2xOk4xOzZ6IN88US=> MoT2V2FPT0WU
ST486 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13hcmlEPTB;MU[uNFQ{OSEQvF2= NWPLNVhOW0GQR1XS
BB30-HNC NGr2UZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1zNj6xNlQ3KM7:TR?= MorlV2FPT0WU
EGI-1 NW[1fIVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK5TWM2OD1zNj60OFYh|ryP NGXFTnFUSU6JRWK=
SH-4 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4LkS3N|Eh|ryP M1fjNnNCVkeHUh?=
MN-60 NU\G[oN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnZcnBCUUN3ME2xO{4zOjl5IN88US=> MoHOV2FPT0WU
MPP-89 M{ntUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF5LkK0OVkh|ryP NXP0PFZZW0GQR1XS
A2780 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrhWG1TUUN3ME2xO{41OTN7IN88US=> M1:3NXNCVkeHUh?=
Daoy MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfxZZRbUUN3ME2xO{41Pjl3IN88US=> MULTRW5ITVJ?
NCI-H2126 NUewSGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF5LkS3O|Eh|ryP M1\tZnNCVkeHUh?=
NCI-H1563 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zp[WlEPTB;MUeuOFkyPyEQvF2= MlSwV2FPT0WU
8-MG-BA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;UfWVKSzVyPUG3MlY3PDhizszN NHn5RpJUSU6JRWK=
786-0 NYHkeHY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L5VWlEPTB;MUeuPFM2OyEQvF2= M4XNPHNCVkeHUh?=
AM-38 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF5LkmzNFYh|ryP NInETWNUSU6JRWK=
COLO-824 NYO3bnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37EUmlEPTB;MUiuOFQ{PiEQvF2= MUfTRW5ITVJ?
SK-MEL-30 NETLeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTlZ4F2UUN3ME2xPE42ODh{IN88US=> MmLjV2FPT0WU
CESS MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW1TWM2OD1zOD63OlA6KM7:TR?= MVXTRW5ITVJ?
BL-70 NGe5O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrGOY44UUN3ME2xPE45OTV4IN88US=> NIDFd|lUSU6JRWK=
NCI-H2170 NGLnN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrMTWM2OD1zOD65NVc6KM7:TR?= NF30SJVUSU6JRWK=
HT-3 M3\DNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj4Sm1KSzVyPUG4Mlk5OyEQvF2= NUj2VlI6W0GQR1XS
BOKU MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor2TWM2OD1zOT6wN|gyKM7:TR?= NHXF[phUSU6JRWK=
HPAF-II NVq3W4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF7LkOwNVUh|ryP NHnXWFlUSU6JRWK=
KGN Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPtWZBKSzVyPUG5MlQ4PjVizszN MWrTRW5ITVJ?
MC-CAR M2i3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G3TWlEPTB;MUmuOlMyOyEQvF2= M1jwT3NCVkeHUh?=
BHT-101 NYr5UJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHCUGJKSzVyPUG5Mlc4PyEQvF2= NH3IR|FUSU6JRWK=
SW1783 NYrHUo9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnNGRsUUN3ME2xPU44QDB4IN88US=> NWWzSVNzW0GQR1XS
KP-N-YN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1PI5KSzVyPUKwMlAzPjJizszN MknKV2FPT0WU
LU-165 NHOzNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5R|Z5UUN3ME2yNE42PTdzIN88US=> NEjpOVdUSU6JRWK=
GOTO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX2TWM2OD1{MD62OFUyKM7:TR?= Mn7OV2FPT0WU
EFM-19 NXS5SXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4VnlUUUN3ME2yNU4xPzF4IN88US=> M{nXZ3NCVkeHUh?=
CTV-1 NGPtZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJzLkGwOVQh|ryP M13xe3NCVkeHUh?=
HEL NFL6e|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJzLkSyNVYh|ryP M{HJWHNCVkeHUh?=
SNU-C2B M1zvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJzLkSyOkDPxE1? MkHBV2FPT0WU
ECC4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\RO|dMUUN3ME2yNU44ODdizszN NVryUoF5W0GQR1XS
NEC8 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3MRZhKSzVyPUKxMlg{PjhizszN MYDTRW5ITVJ?
KMOE-2 NHOxV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJzLki5NlEh|ryP MUfTRW5ITVJ?
NCI-H524 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxZmtKSzVyPUKyMlA5ODhizszN MX7TRW5ITVJ?
WSU-NHL MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnGflNKSzVyPUKyMlE2PzdizszN M2ryTXNCVkeHUh?=
SF126 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ{LkK0Olkh|ryP M1v0SXNCVkeHUh?=
HOP-92 MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTJ{LkOxOlch|ryP MXfTRW5ITVJ?
CTB-1 NEnWUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TsXWlEPTB;MkKuOFY4PyEQvF2= MX7TRW5ITVJ?
KYSE-270 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TIb2lEPTB;MkKuPVM2PyEQvF2= MUnTRW5ITVJ?
SK-MEL-24 NVL1cZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ|LkG4O{DPxE1? NHrS[mpUSU6JRWK=
Calu-3 M1zlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ|LkKxNlgh|ryP M4PjbnNCVkeHUh?=
GAMG NV7NV45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ|LkKzOlch|ryP MVPTRW5ITVJ?
SW1573 NIm5enBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXztVGVbUUN3ME2yN{44PDF3IN88US=> M4q3bnNCVkeHUh?=
MHH-NB-11 M37IeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqxemNtUUN3ME2yOE4xOTl2IN88US=> MmLEV2FPT0WU
TK10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHoTWM2OD1{ND61NFE{KM7:TR?= MXvTRW5ITVJ?
LB373-MEL-D MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P2NmlEPTB;MkSuOlA3PCEQvF2= NVW5UXhyW0GQR1XS
KALS-1 NHvjNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr5[Jg{UUN3ME2yOE44OzJ5IN88US=> M4L4dXNCVkeHUh?=
HUTU-80 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv0UlhIUUN3ME2yOU45ODN{IN88US=> MYfTRW5ITVJ?
HuP-T3 NYHFWHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTJ4LkG2O|Qh|ryP MVLTRW5ITVJ?
OE19 M4Prb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j1SmlEPTB;Mk[uNlE2OyEQvF2= NHGxOVVUSU6JRWK=
J82 NX3h[lBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnjTWM2OD1{Nj6yOFcyKM7:TR?= Mn;WV2FPT0WU
DU-4475 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW2TWM2OD1{Nj6zPFE6KM7:TR?= NIDoZmFUSU6JRWK=
DMS-53 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7m[4tKSzVyPUK2MlUyOzhizszN NX;XfYRSW0GQR1XS
COLO-741 NIDxVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRTWM2OD1{Nj64N|Q1KM7:TR?= NYrPd|g6W0GQR1XS
SW48 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;FUIFLUUN3ME2yOk45QDJizszN MofZV2FPT0WU
IGR-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jHR2lEPTB;Mk[uPVM{PCEQvF2= NGOxPWtUSU6JRWK=
639-V NVmySmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTCTpBzUUN3ME2yO{4xOjR3IN88US=> MWXTRW5ITVJ?
LK-2 NHmwcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKzTWM2OD1{Nz60NVQyKM7:TR?= NYnKb2IzW0GQR1XS
NCI-H2347 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfENohbUUN3ME2yO{46Pjl7IN88US=> M4HoNnNCVkeHUh?=
NCI-H2228 NFTRV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PXXmlEPTB;MkiuNFkxPSEQvF2= M1y0SXNCVkeHUh?=
LS-123 NWfRNHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDuXo1KSzVyPUK4MlEzPjJizszN MX\TRW5ITVJ?
U031 M1L0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nIU2lEPTB;MkiuNlUzKM7:TR?= NX3pO2M5W0GQR1XS
NCI-H1792 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\NSGlEPTB;MkiuOFczOSEQvF2= M1TZSXNCVkeHUh?=
NCI-H2087 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjOPJN[UUN3ME2yPE44PTV{IN88US=> M1f4XHNCVkeHUh?=
NCI-H2342 NVm4dYtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Ve|BKSzVyPUK5MlUzODhizszN Mlv3V2FPT0WU
SW626 NXLxNFdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXCNVFKSzVyPUK5Mlc2PiEQvF2= MW\TRW5ITVJ?
LB2518-MEL NIfHToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DLcGlEPTB;MkmuPFE2KM7:TR?= NEjK[VNUSU6JRWK=
RXF393 NYD6b401T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[xdnhEUUN3ME2zNE4xQTV{IN88US=> MXPTRW5ITVJ?
LC4-1 M2f0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnFbJZjUUN3ME2zNE4{ODl{IN88US=> MXzTRW5ITVJ?
NCI-H1694 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vkZWlEPTB;M{CuOlYzPCEQvF2= M1PaNXNCVkeHUh?=
K5 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2TWM2OD1|MD65O|AzKM7:TR?= NVvMTI9pW0GQR1XS
HDLM-2 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjRWm9KSzVyPUOwMlk4OjVizszN MWXTRW5ITVJ?
BCPAP M{XxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPYTWM2OD1|MT64N|c6KM7:TR?= M365[HNCVkeHUh?=
BC-3 NYe4XHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojvTWM2OD1|Mj6xOFA{KM7:TR?= NUPYTHZHW0GQR1XS
LB996-RCC M1\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofTTWM2OD1|Mj6yN|U5KM7:TR?= M3vhd3NCVkeHUh?=
NCI-H2009 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\aTWM2OD1|Mj60PVgyKM7:TR?= MXnTRW5ITVJ?
HTC-C3 M3HOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnQfI1OUUN3ME2zN{44PTF7IN88US=> M2PBd3NCVkeHUh?=
LAMA-84 NH3aXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XGNGlEPTB;M{SuOFQxPyEQvF2= NEPOOohUSU6JRWK=
CCRF-CEM NWWw[pRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDyTWM2OD1|ND61O|E2KM7:TR?= MkmzV2FPT0WU
AN3-CA M4DsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\QdmlEPTB;M{WuNFU3QCEQvF2= NHvYNoNUSU6JRWK=
NCI-H1734 NHTSXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\UdWlEPTB;M{WuNlU3OSEQvF2= NX7XWWRbW0GQR1XS
Ca-Ski MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvkTWM2OD1|NT60NVAyKM7:TR?= M2D2d3NCVkeHUh?=
U-266 NUfmOJRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTvTWM2OD1|NT62NVE1KM7:TR?= M2jsRnNCVkeHUh?=
SBC-5 M1;FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\p[3NsUUN3ME2zOU44PzhzIN88US=> MnTYV2FPT0WU
GT3TKB NWDjT3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN5LkGxOUDPxE1? NYfOe2p[W0GQR1XS
MDA-MB-175-VII Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjSd3AxUUN3ME2zO{4zOjR6IN88US=> NVnZNpg5W0GQR1XS
PFSK-1 NUnrZYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTN5LkK0N|Uh|ryP MmH0V2FPT0WU
IMR-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n3WWlEPTB;M{euNlQ5PyEQvF2= NV[3[WkzW0GQR1XS
Daudi MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\RXZpKSzVyPUO3MlM2QTdizszN NH\ZWnlUSU6JRWK=
A498 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjKXXlDUUN3ME2zO{44OjF6IN88US=> MX;TRW5ITVJ?
SCC-4 Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN5Lke4OFMh|ryP NVjTSIl7W0GQR1XS
COLO-680N NITjeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWO5JzUUN3ME2zPE4zQDh3IN88US=> MWLTRW5ITVJ?
SK-MES-1 NH24dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;m[JA1UUN3ME2zPE4{OjF3IN88US=> NU\jSHFIW0GQR1XS
SR NUXHd2tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTN6LkW0PVUh|ryP NUPjZZVQW0GQR1XS
LNCaP-Clone-FGC NWe4Z2FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPxfG1KSzVyPUO4MlU3OzdizszN NFy0RWVUSU6JRWK=
SK-HEP-1 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PtXmlEPTB;M{iuO|gzOiEQvF2= MoW4V2FPT0WU
BPH-1 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\oXodKSzVyPUO4Mlg{OjlizszN MVXTRW5ITVJ?
NCI-H1755 M3PFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ntVWlEPTB;M{muOVgyPyEQvF2= NHPuOWZUSU6JRWK=
LXF-289 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\uZ3JKSzVyPUO5MlgxQDRizszN MWfTRW5ITVJ?
SW1088 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTRyLkKxNFch|ryP NXjlSlJnW0GQR1XS
MOLT-4 M{PJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TLSmlEPTB;NECuNlkxOSEQvF2= MVrTRW5ITVJ?
AsPC-1 M4PjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfNcYtXUUN3ME20NE41PTh|IN88US=> MoXJV2FPT0WU
HOP-62 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6TWM2OD12MD62OVY5KM7:TR?= M1;Sc3NCVkeHUh?=
A172 MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRyLki1NVEh|ryP MXfTRW5ITVJ?
SN12C NUjpUXBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIW4dKUUN3ME20NE46Ozh3IN88US=> NW\zPVBjW0GQR1XS
MDA-MB-231 NFHVd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTRyLkm4PVgh|ryP MkjIV2FPT0WU
RPMI-2650 NHmxcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTTZoVOUUN3ME20NU4yPTl|IN88US=> NVO2cYJCW0GQR1XS
KYSE-140 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRzLkixNlMh|ryP NYPwU|hlW0GQR1XS
KINGS-1 M4[yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u5cmlEPTB;NEKuOFY6PyEQvF2= MY\TRW5ITVJ?
HSC-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrQTWM2OD12Mj62OlYyKM7:TR?= MoXvV2FPT0WU
PC-14 NUHnWlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXxelRCUUN3ME20N{4yQDh{IN88US=> Mn;ZV2FPT0WU
COR-L105 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnvSYFKSzVyPUSzMlY2ODJizszN MXPTRW5ITVJ?
BE-13 NHzpSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLwTWM2OD12ND6yN|cyKM7:TR?= NE\zUmhUSU6JRWK=
NCI-H661 NGjvWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR2LkK5OVgh|ryP NEizUYdUSU6JRWK=
IST-MEL1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XweWlEPTB;NESuN|U6QSEQvF2= NX;hV2V3W0GQR1XS
HCC1806 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7RSGJKSzVyPUS0MlU5PzNizszN NUO3Roc2W0GQR1XS
COLO-800 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTlTWM2OD12ND64OFU{KM7:TR?= NFvhb3BUSU6JRWK=
IST-SL2 M2jSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTR3LkGyOFch|ryP NIm5fmNUSU6JRWK=
8305C M3[xZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPLeFlKSzVyPUS1MlMxQSEQvF2= NGjSTmtUSU6JRWK=
UACC-62 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorjTWM2OD12Nj6yPFc2KM7:TR?= MmCzV2FPT0WU
COR-L23 NVvkT|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTR5LkG5PUDPxE1? NEG0WXJUSU6JRWK=
EFE-184 NHKxeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj5d2tKSzVyPUS3MlM5QCEQvF2= NE\4cWhUSU6JRWK=
DMS-114 NEjNOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS3XVdRUUN3ME20O{41OTR7IN88US=> MVnTRW5ITVJ?
KYSE-520 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPxd2pKSzVyPUS4MlU{OTVizszN NYHXSXRPW0GQR1XS
SNG-M MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M363NWlEPTB;NEmuOFM1KM7:TR?= NHrUWG9USU6JRWK=
A2058 NIr3foVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR7LkS4PFUh|ryP MmfpV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型,抑制肿瘤生长,按 75 mg / kg剂量处理,导致100% TGI和 55% 衰退,按25 mg/kg剂量处理,导致 60% TGI,没有衰退。OSI-906处理犬,大鼠和小鼠,诱导不同的消除半衰期,消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠,每天一次,Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天,提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型,在4 和24小时间最大程度抑制IGF-IR磷酸化(80%),血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠,处理2,4,24小时,抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型,抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中,使用聚 (Glu:Tyr)作为底物,结合到96孔实验板表面,使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物,通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中,人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白,且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验,除非另有说明,取三次测量的最小值。
细胞实验:[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖,细胞接种在含FCS 10%的合适培养基上,在不同浓度OSI-906存在时,温育3天。通过细胞内ATP含量的荧光量化,使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分,通过在不同浓度 OSI-906存在时的细胞密度除以对照组(只用DMSO处理)细胞密度。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理,每天一次,持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O

CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID